438 related articles for article (PubMed ID: 30342955)
1. Evaluation of the effect of 2'-O-methyl, fluoro hexitol, bicyclo and Morpholino nucleic acid modifications on potency of GalNAc conjugated antisense oligonucleotides in mice.
Prakash TP; Yu J; Kinberger GA; Low A; Jackson M; Rigo F; Swayze EE; Seth PP
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3774-3779. PubMed ID: 30342955
[TBL] [Abstract][Full Text] [Related]
2. Conjugation of mono and di-GalNAc sugars enhances the potency of antisense oligonucleotides via ASGR mediated delivery to hepatocytes.
Kinberger GA; Prakash TP; Yu J; Vasquez G; Low A; Chappell A; Schmidt K; Murray HM; Gaus H; Swayze EE; Seth PP
Bioorg Med Chem Lett; 2016 Aug; 26(15):3690-3. PubMed ID: 27268307
[TBL] [Abstract][Full Text] [Related]
3. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.
Prakash TP; Graham MJ; Yu J; Carty R; Low A; Chappell A; Schmidt K; Zhao C; Aghajan M; Murray HF; Riney S; Booten SL; Murray SF; Gaus H; Crosby J; Lima WF; Guo S; Monia BP; Swayze EE; Seth PP
Nucleic Acids Res; 2014 Jul; 42(13):8796-807. PubMed ID: 24992960
[TBL] [Abstract][Full Text] [Related]
4. Characterizing the effect of GalNAc and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptor.
Schmidt K; Prakash TP; Donner AJ; Kinberger GA; Gaus HJ; Low A; Østergaard ME; Bell M; Swayze EE; Seth PP
Nucleic Acids Res; 2017 Mar; 45(5):2294-2306. PubMed ID: 28158620
[TBL] [Abstract][Full Text] [Related]
5. Enhanced Potency of GalNAc-Conjugated Antisense Oligonucleotides in Hepatocellular Cancer Models.
Kim Y; Jo M; Schmidt J; Luo X; Prakash TP; Zhou T; Klein S; Xiao X; Post N; Yin Z; MacLeod AR
Mol Ther; 2019 Sep; 27(9):1547-1557. PubMed ID: 31303442
[TBL] [Abstract][Full Text] [Related]
6. Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes.
Tanowitz M; Hettrick L; Revenko A; Kinberger GA; Prakash TP; Seth PP
Nucleic Acids Res; 2017 Dec; 45(21):12388-12400. PubMed ID: 29069408
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Structure-Activity Relationship of Triantennary N-Acetylgalactosamine Conjugated Antisense Oligonucleotides for Targeted Delivery to Hepatocytes.
Prakash TP; Yu J; Migawa MT; Kinberger GA; Wan WB; Østergaard ME; Carty RL; Vasquez G; Low A; Chappell A; Schmidt K; Aghajan M; Crosby J; Murray HM; Booten SL; Hsiao J; Soriano A; Machemer T; Cauntay P; Burel SA; Murray SF; Gaus H; Graham MJ; Swayze EE; Seth PP
J Med Chem; 2016 Mar; 59(6):2718-33. PubMed ID: 26914862
[TBL] [Abstract][Full Text] [Related]
8. Comparative Characterization of Hepatic Distribution and mRNA Reduction of Antisense Oligonucleotides Conjugated with Triantennary N-Acetyl Galactosamine and Lipophilic Ligands Targeting Apolipoprotein B.
Watanabe A; Nakajima M; Kasuya T; Onishi R; Kitade N; Mayumi K; Ikehara T; Kugimiya A
J Pharmacol Exp Ther; 2016 May; 357(2):320-30. PubMed ID: 26907624
[TBL] [Abstract][Full Text] [Related]
9. Effect of modular conjugation strategy for
Yamamoto T; Sawamura M; Terada C; Kashiwada K; Wada F; Yamayoshi A; Obika S; Harada-Shiba M
Nucleosides Nucleotides Nucleic Acids; 2020; 39(1-3):109-118. PubMed ID: 31617782
[TBL] [Abstract][Full Text] [Related]
10. Solid-phase synthesis of 5'-triantennary N-acetylgalactosamine conjugated antisense oligonucleotides using phosphoramidite chemistry.
Prakash TP; Brad Wan W; Low A; Yu J; Chappell AE; Gaus H; Kinberger GA; Østergaard ME; Migawa MT; Swayze EE; Seth PP
Bioorg Med Chem Lett; 2015 Oct; 25(19):4127-30. PubMed ID: 26299345
[TBL] [Abstract][Full Text] [Related]
11. Targeted Delivery of Antisense Oligonucleotides Using Neurotensin Peptides.
Nikan M; Tanowitz M; Dwyer CA; Jackson M; Gaus HJ; Swayze EE; Rigo F; Seth PP; Prakash TP
J Med Chem; 2020 Aug; 63(15):8471-8484. PubMed ID: 32677436
[TBL] [Abstract][Full Text] [Related]
12. Cholesterol-GalNAc Dual Conjugation Strategy for Reducing Renal Distribution of Antisense Oligonucleotides.
Wada F; Yamamoto T; Ueda T; Sawamura M; Wada S; Harada-Shiba M; Obika S
Nucleic Acid Ther; 2018 Feb; 28(1):50-57. PubMed ID: 29360004
[TBL] [Abstract][Full Text] [Related]
13. In Vivo Metabolite Profiles of an
Li XQ; Elebring M; Dahlén A; Weidolf L
Drug Metab Dispos; 2023 Oct; 51(10):1350-1361. PubMed ID: 37429729
[TBL] [Abstract][Full Text] [Related]
14. Effect of 2'-O-[2-[2-(N,N-dimethylamino)ethoxy]ethyl] modification on activity of gapmer antisense oligonucleotides containing 2',4'-constrained 2'-O-ethyl nucleic acid.
Pandey SK; Nowak A; Perkins J; Ferng A; Prakash TP
Bioorg Med Chem Lett; 2015 Apr; 25(8):1688-1691. PubMed ID: 25804718
[TBL] [Abstract][Full Text] [Related]
15. Serial incorporation of a monovalent GalNAc phosphoramidite unit into hepatocyte-targeting antisense oligonucleotides.
Yamamoto T; Sawamura M; Wada F; Harada-Shiba M; Obika S
Bioorg Med Chem; 2016 Jan; 24(1):26-32. PubMed ID: 26678173
[TBL] [Abstract][Full Text] [Related]
16. Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2'-modifications and enhances antisense activity.
Liang XH; Shen W; Sun H; Kinberger GA; Prakash TP; Nichols JG; Crooke ST
Nucleic Acids Res; 2016 May; 44(8):3892-907. PubMed ID: 26945041
[TBL] [Abstract][Full Text] [Related]
17. Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index.
Shen W; De Hoyos CL; Migawa MT; Vickers TA; Sun H; Low A; Bell TA; Rahdar M; Mukhopadhyay S; Hart CE; Bell M; Riney S; Murray SF; Greenlee S; Crooke RM; Liang XH; Seth PP; Crooke ST
Nat Biotechnol; 2019 Jun; 37(6):640-650. PubMed ID: 31036929
[TBL] [Abstract][Full Text] [Related]
18. Efficient Synthesis and Biological Evaluation of 5'-GalNAc Conjugated Antisense Oligonucleotides.
Østergaard ME; Yu J; Kinberger GA; Wan WB; Migawa MT; Vasquez G; Schmidt K; Gaus HJ; Murray HM; Low A; Swayze EE; Prakash TP; Seth PP
Bioconjug Chem; 2015 Aug; 26(8):1451-5. PubMed ID: 26011654
[TBL] [Abstract][Full Text] [Related]
19. Integrated Assessment of the Clinical Performance of GalNAc
Crooke ST; Baker BF; Xia S; Yu RZ; Viney NJ; Wang Y; Tsimikas S; Geary RS
Nucleic Acid Ther; 2019 Feb; 29(1):16-32. PubMed ID: 30570431
[TBL] [Abstract][Full Text] [Related]
20. Safety, Pharmacokinetic, and Pharmacodynamic Evaluation of a 2'-(2-Methoxyethyl)-D-ribose Antisense Oligonucleotide-Triantenarry
Zanardi TA; Korbmacher B; Boone L; Engelhardt JA; Wang Y; Burel S; Prill B; Aghajan M; Guo S; Henry SP
J Pharmacol Exp Ther; 2021 Apr; 377(1):51-63. PubMed ID: 33431610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]